Crown Laboratories to Acquire Botox Rival Revance Therapeutics for $924M

Acquisition Details:
Crown Laboratories, a privately held skincare company, has agreed to acquire Revance Therapeutics, the maker of the Botox rival Daxxify, for $924 million.

Deal Structure:
The acquisition will be conducted through a tender offer where Crown will purchase all outstanding shares of Revance's common stock for $6.66 per share in cash.

Companies Involved:
Revance Therapeutics is based in Nashville, Tennessee, while Crown Laboratories is headquartered in Johnson City, Tennessee.

Timeline:
The acquisition is expected to be completed by the end of the year.

Impact:
This deal marks a significant move in the skincare and pharmaceutical industries, as Revance will transition from a publicly traded company to a private entity under Crown Laboratories.